全文获取类型
收费全文 | 18688篇 |
免费 | 713篇 |
国内免费 | 598篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 520篇 |
妇产科学 | 86篇 |
基础医学 | 1518篇 |
口腔科学 | 33篇 |
临床医学 | 2249篇 |
内科学 | 2097篇 |
皮肤病学 | 145篇 |
神经病学 | 161篇 |
特种医学 | 1198篇 |
外科学 | 5594篇 |
综合类 | 2667篇 |
预防医学 | 717篇 |
眼科学 | 12篇 |
药学 | 1676篇 |
9篇 | |
中国医学 | 477篇 |
肿瘤学 | 813篇 |
出版年
2023年 | 153篇 |
2022年 | 381篇 |
2021年 | 569篇 |
2020年 | 505篇 |
2019年 | 506篇 |
2018年 | 571篇 |
2017年 | 530篇 |
2016年 | 522篇 |
2015年 | 577篇 |
2014年 | 1205篇 |
2013年 | 1129篇 |
2012年 | 1078篇 |
2011年 | 1066篇 |
2010年 | 884篇 |
2009年 | 1016篇 |
2008年 | 1026篇 |
2007年 | 971篇 |
2006年 | 852篇 |
2005年 | 771篇 |
2004年 | 590篇 |
2003年 | 521篇 |
2002年 | 381篇 |
2001年 | 392篇 |
2000年 | 361篇 |
1999年 | 273篇 |
1998年 | 275篇 |
1997年 | 240篇 |
1996年 | 220篇 |
1995年 | 236篇 |
1994年 | 231篇 |
1993年 | 174篇 |
1992年 | 209篇 |
1991年 | 160篇 |
1990年 | 152篇 |
1989年 | 127篇 |
1988年 | 167篇 |
1987年 | 110篇 |
1986年 | 80篇 |
1985年 | 76篇 |
1984年 | 77篇 |
1983年 | 35篇 |
1982年 | 78篇 |
1981年 | 66篇 |
1980年 | 84篇 |
1979年 | 63篇 |
1978年 | 50篇 |
1977年 | 49篇 |
1976年 | 46篇 |
1975年 | 30篇 |
1973年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 562 毫秒
11.
Lara Feulner Hamed S. Najafabadi Simon Tanguay Janusz Rak Yasser Riazalhosseini 《Urologic oncology》2019,37(2):166-175
Background
Clear cell renal cell carcinoma (ccRCC) is known to occur across the adult lifetime traversing the spectrum of age-related organismal changes. Little is known as to how the aging process may affect the course of renal cell carcinoma (RCC) and the repertoire of genes involved.Methods
Using The Cancer Genome Atlas (n?=?436) and Cancer Genomics of the Kidney (n?=?89) datasets, we applied regression analysis to examine associations between patient age and gene expression profiles in ccRCC tumors and normal kidney tissues. Pathway enrichment analysis was performed to identify cellular process that is affected by aging in ccRCC. Moreover, connectivity mapping analysis was used to predict age-dependent response to drug treatments.Results
Our analysis revealed different age-dependent gene expression spectra in ccRCC and normal kidney tissues. These findings were significant and independently reproducible in both datasets examined. Age up-regulated genes, showing higher expression in older patients, were significantly enriched (false discovery rate <0.05) in normal tissues for pathways associated with immune response and extracellular matrix organization, whereas age up-regulated genes in tumors were enriched for metabolism and oxidation pathways. Strikingly, age down-regulated genes in normal cells were also enriched for metabolism and oxidation, while those in tumors were enriched for extracellular matrix organization. Further in silico analysis of potential drug targets predicted preferential efficacy of Phosphoinositide 3-kinase inhibitor or immunotherapy in association with age.Conclusion
We report on previously unrecognized associations between age and molecular underpinnings of RCC, including age-associated expression of genes implicated in RCC development or treatment. 相似文献12.
目的对比研究腹腔镜下外生性肾血管平滑肌脂肪瘤"蘑菇状"剜除与标准肾部分切除术的安全性及有效性,为肾血管平滑肌脂肪瘤腹腔镜下"蘑菇状"剜除术术式的建立提供临床依据。
方法选取海南医学院第二附属医院与解放军总医院2018年1月至2019年5月期间,接受腹腔镜手术的肾血管平滑肌脂肪瘤患者53例,其中25例沿肿瘤假包膜行"蘑菇状"剜除术(A组)、28例行肾部分切除术(B组)。比较两组手术患者的肾动脉阻断时间、手术时间、术中出血量、术后24 h血红蛋白、术后eGFR(estimated glomerular filtration rate,估计肾小球率过滤)的变化、术后住院时间和术后肿瘤复发率。
结果53例手术无术中转开放,无死亡病例。肾动脉阻断时间:A组(11.9±2.2)min、B组(21.5±6.5) min(P<0.001)。手术时间:A组(87.9±24.8)min、B组(114.3±38.9) min(P<0.001)。术中出血量:A组20 ml(20~40)ml、B组50 ml(50~100)ml(P<0.001)。术后24 h血红蛋白变化:A组(7.4±4.3) g/L、B组(12.4±8.8) g/L(P=0.013)。术后24 h eGFR变化:A组(6.2±7.2 )ml(min·1.73 m2),B组(12.7±12.8)ml(min·1.73 m2)(P=0.027)。术后6个月eGFR变化:A组(1.5±3.7)ml(min·1.73 m2)、B组(6.5±5.6)ml(min·1.73 m2)(P<0.001)。术后住院时间:A组4.0 d(3~4)d、B组4.5 d(3~6)d(P=0.023)。术后随访两组术后肿瘤均无复发。
结论采用腹腔镜"蘑菇状"剜除术治疗外生性肾血管平滑肌脂肪瘤在肾动脉阻断时间、术中出血量、术后24 h血红蛋白、术后eGFR变化、术后住院时间等方面均优于传统肾部分切除术,两组术后肿瘤均无复发;该方法安全、有效,适于临床推广。 相似文献
13.
《European Urology Supplements》2015,14(1):9-11
The main goal in the management of patients with vesicoureteral reflux (VUR) is the preservation of kidney function by minimizing the risk of pyelonephritis. By defining and analyzing the risk factors for each patient depending on age, sex, grade of reflux, lower urinary tract dysfunction, anatomic abnormalities, and kidney status, it is possible to identify those patients with a potential risk of upper urinary tract infection and resulting renal scarring. This paper gives a brief overview of the European Association of Urology guidelines for the management and treatment of VUR in children. These guidelines are based on the best currently available knowledge and evidence. 相似文献
14.
《Surgical pathology clinics》2015,8(4):587-621
According to the current World Health Organization (WHO), renal cell carcinomas (RCCs) that primarily affect adults are classified into 8 major subtypes. Additional emerging entities in renal neoplasia have also been recently recognized and these are discussed in further detail by Mehra et al (Emerging Entities in Renal Neoplasia, Surgical Pathology Clinics, 2015, Volume 8, Issue 4). In most cases, the diagnosis of a RCC subtype can be based on morphologic criteria, but in some circumstances the use of ancillary studies can aid in the diagnosis. This review discusses the morphologic, genetic, and molecular findings in RCCs previously recognized by the WHO, and provides clues to distinction from each other and some of the newer subtypes of RCC. As prognosis and therapeutic options vary for the different subtypes of RCC, accurate pathologic distinction is critical for patient care. 相似文献
15.
Objective To analyze the early mortality and related risk factors of new hemodialysis patients in Zhejiang province, and provide basis for reducing the death risk of hemodialysis patients. Methods The early mortality and related factors of new hemodialysis patients from January 1, 2010 to June 30, 2018 were retrospectively analyzed using the database of Zhejiang province hemodialysis registration. The early mortality was defined as death within 90 days of dialysis. Cox regression model was used to analyze the related risk factors of the early mortality in hemodialysis patients. Results The mortality was the highest in the first month after dialysis (46.40/100 person year), and gradually stabilized after three months. The early mortality was 25.33/100 person year. The mortality within 120 days and 360 days were 21.40/100 person year and 11.37/100 person year, respectively. The elderly (≥65 years old, HR=1.981, 95%CI 1.319-2.977, P<0.001), primary tumor (HR=3.308, 95%CI 1.137-5.624, P=0.028), combined with tumors (not including the primary tumor, HR=2.327, 95%CI 1.200-4.513, P=0.012), temporary catheter (the initial dialysis pathway, HR=3.632, 95%CI 1.806-7.307, P<0.001), lower albumin (<30 g/L, HR=2.181, 95%CI 1.459-3.260, P<0.001), lower hemoglobin (every 0.01 g/L increase, HR=0.861, 95%CI 0.793-0.935, P=0.001), lower high density lipoprotein (<0.7 mmol/L, HR=1.796, 95%CI 1.068-3.019, P=0.027) and higher C reactive protein (≥40 mg/L, HR=1.889, 95%CI 1.185-3.012, P=0.008) were the risk factors of early death for hemodialysis patients. Conclusions The early mortality of hemodialysis patients is high after dialysis, and gradually stable after 3 months. The elderly, primary tumor, combined with tumors, the initial dialysis pathway, lower albumin, lower hemoglobin, lower high density lipoprotein and higher C reactive protein are the risk factors of early death for hemodialysis patients. 相似文献
16.
多巴胺或多巴胺复合去甲肾上腺素对肝移植术中患者血液动力学、氧代谢及肾功能的影响 总被引:3,自引:0,他引:3
目的评价原位肝脏移植术(OLT)中持续输注多巴胺或多巴胺复合去甲肾上腺素对血液动力学、组织氧代谢和肾功能的影响。方法拟行OLT的患者30例,ASAⅢ或Ⅳ级,随机分为2组 (n=15)。A组:术中持续输注多巴胺,初始输注速率为1-3μg·kg-1·min-1;B组:术中持续输注多巴胺复合去甲肾上腺素,初始输注速率分别为1-3μg·kg-1·min-1和0.03μg·kg-1·min-1,多巴胺输注速率不超过5μg·kg-1·min-1;术中两组均调节输注速率维持MAP 60-80 mm Hg。分别于切皮前即刻、切肝期1 h、无肝期1 h、新肝期1h和术毕测定血液动力学、组织代谢和肾功能指标。结果两组HR、 MAP均维持较平稳。无肝期两组CVP、MPAP、PAWP、CO、CI、DO2、VO2降低(P<0.05);SVR和SVRI升高(P<0.05),但均在正常范围内。术中PVR、PVRI、pH及SvO2均较平稳。乳酸浓度增高并持续到术毕。两组术中Cr和BUN均在正常范围,B组总尿量高于A组(P相似文献
17.
Smart Prep技术在肾动脉CTA中的临床应用 总被引:3,自引:0,他引:3
目的:探讨Smart Prep技术在肾动脉多层螺旋CT血管造影中的应用。方法:20例行同层动态增强扫描,通过时间-密度曲线获得肾动脉的有效浓度阈值。65例行肾动脉CTA造影,经肘静脉团注370mgI/ml优维显1.5ml/kg后,应用Smart Prep软件实时监控靶血管浓度,当感兴趣区对比剂浓度达有效浓度阈值时触发增强扫描完成数据采集,重组和重建图像显示肾动脉。结果:65例肾动脉CTA造影均获成功,58例(89.2%)增强时相处于最佳扫描时期。增强扫描的延迟时间15~38s不等,个体差异明显,而肾动脉CT值持续位于有效浓度阈值(100HU)以上。结论:Smart Prep技术实时监控肾动脉对比剂浓度变化并及时触发增强扫描,它不受个体差异影响即可确保增强扫描的实施,优于小剂量试验。 相似文献
18.
19.
马兜铃酸对大鼠肾功能和组织病理学影响及川芎嗪与苯那普利的干预作用 总被引:1,自引:0,他引:1
目的:通过动物实验,观察大鼠灌胃马兜铃酸(AA)后,肾功能及肾脏组织病理学改变,及川芎嗪、苯那普利对肾损害的干预作用.方法:雄性Wistar大鼠98只,SPF级,随机分为4组:正常对照组20只,实验组分为模型组、川芎嗪组、苯那普利组,每组26只;各实验组按AA 20 mg·kg-1·d-1关木通浸膏灌胃,2 h后按分组灌胃给药.川芎嗪50 mg·kg-1·d-1,苯那普利1.8 mg·kg-1·d-1;正常对照组、模型组灌胃饮用水.各组每周测量体重,分别于第4、8、12周处死动物;腹主动脉采血分离血清,检测肾功能;取肾组织进行病理形态学检查.结果:AA灌胃4周后各组血肌酐/体重水平明显增加,与正常对照组比较有统计学差异;与模型组比较,川芎嗪、苯那普利组血肌酐/体重水平显著降低,提示有改善肾功能作用.肾脏组织病理学可见模型组早期有明显的肾小管坏死,部分小管结构紊乱较严重,空泡变性明显;后期出现间质灶性纤维化,纤维化面积>30%.川芎嗪、苯那普利治疗组的肾功能和组织学损害程度较轻微,纤维化程度约15%~20%.结论:马兜铃酸对大鼠肾脏具有肾毒性,可导致小管间质损害和肾纤维化.川芎嗪、苯那普利对马兜铃酸肾损害有保护作用,能减轻马兜铃酸造成的肾组织病理损害,减少肾纤维化程度. 相似文献
20.
目的比较背驮式原位肝移植术中持续输注小剂量多巴胺或呋塞米和多巴胺联合应用对无肝期肾功能和尿量的影响。方法背驮式原位肝移植术患者42例,ASAⅢ~Ⅳ级,随机分为多巴胺组(D组)和呋塞米-多巴胺组(F组),每组21例。两组均于麻醉诱导后静脉泵注多巴胺(2~5μg.kg-1.min-1)至术毕,F组则在无肝期开始时静注呋塞米0.1mg/kg。观察无肝期输液量、血液动力学和尿量,检测血清肌酐(Cr)和肌酐清除率(CCr)。结果与D组比较,F组无肝期尿量明显增多(P<0.05);两组无肝期时间、输液量和心率(HR)、平均动脉压(MAP)、中心静脉压(CVP)、每搏量(SV)、心输出量(CO)、全身血管阻力(TSVR)、Cr、CCr差异无显著意义。结论肝移植术中持续泵注多巴胺和呋塞米联合应用可明显增加无肝期尿量。 相似文献